{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:26:03Z","timestamp":1787865963852,"version":"build-2784847793"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with pancreatic neuroendocrine neoplasms (P-NEN) may benefit from peptide receptor radionuclide therapy (PRRT). Prediction of overall survival (OS) using statistical models has the potential to guide treatment decisions. In this study, we have generated a clinicopathological and imaging parameter-based internally validated nomogram of patients who received PRRT for metastatic P-NEN to facilitate treatment decision support for the clinical management of such patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We reviewed 447 pancreatic NEN patients treated with PRRT. Clinical variables for the prediction of overall survival (OS) included age, gender, Karnofsky performance score (KPS), weight loss, hepatomegaly, time from diagnosis to first PRRT (days), tumor functionality, presence of Hedinger syndrome, presence of liver metastases, presence of bone metastases, presence of lung metastases, alkaline phosphatase, 2-deoxy-2-[18F]fluoro-D-glucose ([<jats:sub>18<\/jats:sub>F]FDG) positron emission tomography (PET) scan positivity, erythrocytes, platelets, creatinine clearance, leucocytes, and histologic grade of tumor differentiation based on KI-67 staining. A random survival forests (RSF) method was used to construct a model with an optimal number of clinical variables. The model was developed on 80% of the data and tested on the remaining 20% of the data. Performance of prediction was calculated using the c-index, a generalization of the area under the ROC curve (AUC) for survival models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median follow up time was 2045 days (min 136 days, max 10329 days). Time from diagnosis to 1<jats:sup>st<\/jats:sup> PRRT, alkaline phosphatase, KPS, hepatomegaly, weight loss, [<jats:sub>18<\/jats:sub>F]FDG-PET scan positivity, Ki-67% derived histologic grade, lung metastases, age, presence of bone metastases, platelet count, erythrocyte count, creatinine clearance, hemoglobin, presence of functioning tumor, creatinine, and gender, were in order of importance, all independent predictors for overall survival. The development set c-index was 0.86, while the test set c-index was 0.82. A nomogram was constructed based on the optimal number of clinical parameters selected in the RSF model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study proposes an internally validated nomogram (PANEN-N) to accurately predict overall survival for P-NEN patients following PRRT, which could be used for patient counseling to facilitate informed and shared decision support in daily clinical practice as well as for generating new hypotheses.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1514792","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:10:21Z","timestamp":1750738221000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Aviral","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sanduleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad R.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Langbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lambin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0120","article-title":"Differences in survival by histologic type of pancreatic cancer","volume":"14","author":"Fesinmeyer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30323-5","article-title":"Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy","volume":"21","author":"Bodei","year":"2020","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.04.008","article-title":"The new world health organization classification for pancreatic neuroendocrine neoplasia","volume":"47","author":"Inzani","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v121.4","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000472254","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biochemical markers","volume":"105","author":"Oberg","year":"2017","journal-title":"Neuroendocrinology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"a002329","DOI":"10.1101\/mcs.a002329","article-title":"Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing","volume":"4","author":"Wong","year":"","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3967-6","article-title":"PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy","volume":"45","author":"Bodei","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ecl.2018.05.002","article-title":"The NETest","volume":"47","author":"Modlin","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B10","unstructured":"FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors [Internet]"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00186-2","article-title":"Consensus on biomarkers for neuroendocrine tumour disease","volume":"16","author":"Oberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7150\/thno.18068","article-title":"Dual somatostatin receptor\/FDG PET\/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance","volume":"7","author":"Chan","year":"2017","journal-title":"Theranostics"},{"key":"B13","article-title":"Management of local and distant recurrence after pancreatic cancer resection","volume-title":"Pancreatic Cancer, Cystic Neoplasms and Endocrine Tumors: Diagnosis and Management","author":"Okusaka","year":"2016"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","author":"Baum","year":"2018","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"B18","unstructured":"Silver Spring: FDA approves new treatment for certain digestive tract cancers. [News release 2018 Jan 26]"},{"key":"B19","unstructured":"Find medicine - Lutathera. [First published 2018 Jan 17]"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/SLA.0b013e31815b9cae","article-title":"Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients","volume":"247","author":"Bilimoria","year":"2008","journal-title":"Ann Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000319784","article-title":"A nomogram to assess small-intestinal neuroendocrine tumor (\u2018Carcinoid\u2019) survival","volume":"92","author":"Modlin","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0194-8","article-title":"Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan","volume":"45","author":"Ito","year":"2010","journal-title":"J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2012.44.3.157","article-title":"Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in korea 2000-2009: multicenter study","volume":"44","author":"Cho","year":"2012","journal-title":"Cancer Res Treat"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1038\/s41598-018-24072-0","article-title":"A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms","volume":"8","author":"Gao","year":"2018","journal-title":"Sci Rep"},{"key":"B28","unstructured":"Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET) (SEQTOR) [cited 2020 Mar 5]"},{"key":"B29","unstructured":"Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM) [cited 2018 Jul 23]"},{"key":"B30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40336-014-0054-2","article-title":"Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments","volume":"2","author":"Bison","year":"2014","journal-title":"Clin Transl Imaging"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9345-4","article-title":"Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors","volume":"51","author":"Clancy","year":"2006","journal-title":"Dig Dis Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0177971","DOI":"10.1371\/journal.pone.0177971","article-title":"An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value","volume":"12","author":"Andriantsoa","year":"2017","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.125336","article-title":"Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J Nucl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.244798","article-title":"18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study","volume":"62","author":"Binderup","year":"2021","journal-title":"J Nucl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high\u2212dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"B38","first-page":"279","volume-title":"WHO Classification of Tumours of the Digestive System. Tumours of the pancreas","author":"Nagtegaal","year":"2010"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000443167","article-title":"Vienna consensus conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1241724","article-title":"Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms","volume":"14","author":"Yao","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B43","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. Journal of nuclear medicine, 2005: official publication","volume":"46","author":"Valkema","year":"","journal-title":"Soc Nucl Med"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-17235-4","volume-title":"Pancreatic neuroendocrine neoplasms. Practical approach to diagnosis, classification, and therapy","author":"La Rosa","year":"2015"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S174907","article-title":"Prognosis of patients with neuroendocrine tumor: a SEER database analysis","volume":"10","author":"Man","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1161\/CIRCULATIONAHA.114.014508","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1514792\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T04:10:23Z","timestamp":1750738223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1514792\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":46,"alternative-id":["10.3389\/fendo.2025.1514792"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1514792","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"article-number":"1514792"}}